Eir Ventures
Overview
Eir Ventures is a Nordic life science venture fund that invests in companies at early stage, as well as more mature opportunities . The fund seeks investment opportunities addressing significant unmet medical needs for new therapies, medical technology and digital health .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Galecto Biotech | Sep 2020 | Series D | Lead |
| Attgeno AB | Oct 2023 | Early Funding | Co-investor |
| Hoba Therapeutics | Dec 2023 | Series A | Co-investor |
| Strike Pharma | Feb 2022 | Seed | Lead |
| ArgusEye | Apr 2026 | VC Round | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Eir Ventures based?
Eir Ventures is headquartered in Sweden.
When was Eir Ventures founded?
Eir Ventures was founded in 2020.
How many portfolio companies does Eir Ventures have?
Eir Ventures has 13 portfolio companies in Caplight's dataset.
What are some companies in Eir Ventures's portfolio?
Portfolio companies visible on Caplight include Galecto Biotech, Attgeno AB, Hoba Therapeutics, Strike Pharma, ArgusEye.
What was Eir Ventures's most recent investment shown here?
Eir Ventures's most recent investment in this portfolio sample was in ArgusEye in 2026.
What sectors does Eir Ventures focus on?
Eir Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Cybersecurity, AI, Data & Cloud Infrastructure, Consumer & Commerce, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Eir Ventures focus on?
Eir Ventures typically invests at the Early stage.
What is Eir Ventures's AUM?
Eir Ventures's assets under management are estimated between $100.0M and $250.0M.